Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of posttraumatic neuralgia with Botulinumtoxin-A vs placebo
DRKS00013548Phase 2Withdrawn
- Sponsor
- Abteilung für SchmerzmedizinBerufsgenossenschaftliches Universitätklinikum Bergmannsheil gGmbH Bochum Bürkle-de-la-Camp-Platz 1
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in post-traumatic neuralgia (2 arms), sponsored by Abteilung für SchmerzmedizinBerufsgenossenschaftliches Universitätklinikum Bergmannsheil gGmbH Bochum Bürkle-de-la-Camp-Platz 1. Planned start Dec 2017; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
post-traumatic neuralgia
Beyond the preview
Go deeper on DRKS00013548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013548.